B-cell Acute Lymphoblastic Leukemia
Showing 1 - 25 of 62
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- +2 more
- CD19/CD22-bispecific CAR-T cells
-
Beijing, Beijing, ChinaLiang Wang
Oct 7, 2023
B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- (no location specified)
Oct 10, 2023
B-cell Acute Lymphoblastic Leukemia Trial in Hefei (QH103 Cell Injection, Fludarabine, Cyclophosphamide)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- QH103 Cell Injection
- +2 more
-
Hefei, Anhui, ChinaAnhui Provincial Hospital
Sep 21, 2023
B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia Trial in Hanoi (anti-CD19 CAR T-cells)
Recruiting
- B-Cell Non Hodgkin Lymphoma
- B-Cell Acute Lymphoblastic Leukemia
- anti-CD19 CAR T-cells
-
Hanoi, VietnamVinmec Research Institute of Stem Cell and Gene Technology
Sep 5, 2023
B-cell Acute Lymphoblastic Leukemia Trial (HY004, Cyclophosphamide, Fludarabine Phosphate)
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- HY004
- +2 more
- (no location specified)
Aug 18, 2023
B-cell Acute Lymphoblastic Leukemia Trial in Hefei (Metabolically Armed CD19 CAR-T cells)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- Metabolically Armed CD19 CAR-T cells
-
Hefei, Anhui, ChinaAnhui Provincial Hospital
Feb 17, 2023
B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- B Lineage Lymphoblastic Lymphoma
- Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
- Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Jan 25, 2023
B-cell Acute Lymphoblastic Leukemia Trial (single dose of CNCT19)
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- single dose of CNCT19
- (no location specified)
Dec 19, 2022
B-cell Acute Lymphoblastic Leukemia Trial in Nanchang (Human CD19 Targeted DASH CAR-T Cells Injection)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- Human CD19 Targeted DASH CAR-T Cells Injection
-
Nanchang, Jiangxi, ChinaThe Second Affiliated Hospital of Nanchang University
Dec 13, 2022
Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children, Lymphoblastic Leukemia, Acute Adult Trial in Singapore (Anti-CD19
Recruiting
- Lymphoblastic Leukemia
- +5 more
- Anti-CD19 CAR T-cells
-
Singapore, Singapore
- +1 more
Dec 4, 2022
B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (UCAR-T Cells)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- B-ALL
- UCAR-T Cells
-
Kunming, Yunnan, China920th Hospital of Joint Logistics Support Force of People's Libe
Dec 7, 2022
B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (U-CAR-T Cells (LstCAR019))
Withdrawn
- B-cell Acute Lymphoblastic Leukemia
- B-ALL
- U-CAR-T Cells (LstCAR019)
-
Kunming, Yunnan, ChinaKunming Hope of Health Hospital
Nov 27, 2022
B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, Unspecified Trial in Guangzhou, Guanzhou (CD19 CAR T-Cell(CAT19T2))
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- B-Cell Lymphoma, Unspecified
- CD19 CAR T-Cell(CAT19T2)
-
Guangzhou, Guangdong, China
- +1 more
Nov 4, 2022
B-cell Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma Trial in Aurora (CD19CAR-CD3Zeta-4-1BB-Expressing Autologous
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- B-cell Non Hodgkin Lymphoma
- CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
-
Aurora, ColoradoChildren's Hospital Colorado
Nov 9, 2022
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma Trial in Canada, Japan (CTL019)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- Diffuse Large B-cell Lymphoma
- CTL019
-
Hamilton, Ontario, Canada
- +41 more
Oct 17, 2022
B-cell Acute Lymphoblastic Leukemia Trial in Suzhou (Blinatumomab, Conventional therapy)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- Blinatumomab
- Conventional therapy
-
Suzhou, Jiangsu, ChinaThe first affiliated hospital of Soochow University
Sep 26, 2022
B-cell Acute Lymphoblastic Leukemia Trial in France, United States (UCART22)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- UCART22
- CLLS52
-
Los Angeles, California
- +10 more
Sep 23, 2022
B-cell Acute Lymphoblastic Leukemia Trial in United States (Inotuzumab ozogamicin, Prednisone Pill, Daunorubicin)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- Inotuzumab ozogamicin
- +6 more
-
Nashville, Tennessee
- +3 more
Aug 14, 2022
B-cell Acute Lymphoblastic Leukemia Trial in Suzhou (CD22/CD19 CAR T and auto-HSCT "sandwich" strategy)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- CD22/CD19 CAR T and auto-HSCT "sandwich" strategy
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Jul 20, 2022
B-cell Acute Lymphoblastic Leukemia Trial in New York (Tisagenlecleucel)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- Tisagenlecleucel
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jul 13, 2022
B-cell Acute Lymphoblastic Leukemia, Obesity Trial in United States (IDEAL2 Intervention)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- Obesity
- IDEAL2 Intervention
-
Los Angeles, California
- +15 more
Jun 23, 2022
B-cell Acute Lymphoblastic Leukemia Trial in Worldwide (CTL019)
Active, not recruiting
- B-cell Acute Lymphoblastic Leukemia
- CTL019
-
Los Angeles, California
- +24 more
Jun 23, 2022
B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Taipei (RPM
Terminated
- B-cell Acute Lymphoblastic Leukemia
- +7 more
- RPM CD19-mbIL15-CAR-T cells
-
Taipei, TaiwanNational Taiwan University Hospital
May 11, 2022
B-cell Lymphoma, B-cell Acute Lymphoblastic Leukemia Trial in Hangzhou (QN-019a, Rituximab, Cyclophosphamid)
Recruiting
- B-cell Lymphoma
- B-cell Acute Lymphoblastic Leukemia
- QN-019a
- +4 more
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital of Medical College of Zhejiang Uni
May 17, 2022